BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 25444514)

  • 1. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
    Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
    Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
    Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
    Beck J; Bellmunt J; Escudier B
    Med Oncol; 2011 Dec; 28(4):1379-83. PubMed ID: 20593250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
    Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
    Maute L; Grünwald V; Weikert S; Kube U; Gauler T; Kahl C; Burkholder I; Bergmann L
    J Cancer Res Clin Oncol; 2014 May; 140(5):823-7. PubMed ID: 24556802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of renal cell carcinoma].
    Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
    Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
    Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
    Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
    BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
    Siebels M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Urologe A; 2011 Sep; 50(9):1110-7. PubMed ID: 21559917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy in metastatic renal cell carcinoma.
    Bedke J; Gauler T; Grünwald V; Hegele A; Herrmann E; Hinz S; Janssen J; Schmitz S; Schostak M; Tesch H; Zastrow S; Miller K
    World J Urol; 2017 Feb; 35(2):179-188. PubMed ID: 27277600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
    Calvani N; Morelli F; Chiuri V; Gnoni A; Scavelli C; Fedele P; Orlando L; Maiello E; Lorusso V; Cinieri S
    Med Oncol; 2013; 30(2):578. PubMed ID: 23613183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.